, Tracking Stock Market Picks
Enter Symbol:
Hospira Inc (HSP) [hlAlert]

down 65.02 %

Hospira Inc (HSP) rated Underperform by Raymond James

Posted on: Thursday,  May 2, 2013  8:25 AM ET by Raymond James

Raymond James rated Underperform Hospira Inc (NYSE: HSP) on 05/02/2013, when the stock price was $31.45. Since
then, Hospira Inc has gained 185.91% as of 09/01/2015's recent price of $89.92.
If you would have followed this Raymond James's recommendation on HSP, you would have lost 65.02% of your investment in 852 days.

Hospira Inc is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness by developing, manufacturing and marketing products that help improve the safety and efficacy of patient care. Their portfolio includes one of the industry's broadest lines of generic acute-care injectables, integrated solutions for medication management and infusion therapy, and a full-service contract manufacturing business.

Our equity research team has gained national attention for stock-picking ability and analyst performance, with recognition in leading publications such as the Wall Street Journal and Institutional Investor magazine*. Raymond James’ equity research philosophy focuses on a fundamental approach that encompasses three basic points. First, we believe that superior research on select companies within well-defined industries is preferable to broad general coverage. Second, we concentrate on the identification of quality companies demonstrating solid growth potential, with the goal of helping our clients maximize their investment returns. Third, to help our clients take advantage of pockets of inefficiency in the market, we strive to locate superior companies from across the country that have the potential to provide our clients with unique opportunities.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/2/2013 8:25 AM Sell
as of 12/13/2013
1 Week up  4.06 %
1 Month down  -1.39 %
3 Months down  -0.65 %
1 YTD down  -26.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy